Profile data is unavailable for this security.
About the company
Ion Beam Applications SA (IBA) is a Belgium-based company that develops and markets technologies, pharmaceutical products and tailored solutions for the healthcare sector, with emphasis on cancer diagnosis and therapy. IBA is also active in the sterilization and ionization field. The Company operates through two business segments, namely the pharmaceuticals segment, which includes radiopharmaceuticals and the equipments segment, which encompasses proton therapy, particle accelerators and dosimetry. Through its various subsidiaries, Ion Beam Applications SA is active in a number of countries, including Belgium, Germany, France, Italy, Spain, the United Kingdom, Sweden, the United States, India and China. In November 2013, the Company announced the closing of the sale of 100% of its business unit Cisbio Bioassays.
- Revenue in EUR (TTM)465.75m
- Net income in EUR7.85m
- Incorporated1986
- Employees1.84k
- LocationIon Beam Applications SAChemin du Cyclotron 3LOUVAIN-LA-NEUVE 1348BelgiumBEL
- Phone+32 10475811
- Fax+32 10475810
- Websitehttps://iba-worldwide.com
More ▼
Mergers & acquisitions
| Acquired company | IBAB:BRU since announced | Transaction value |
|---|---|---|
| Radcal Corp | 36.11% | -- |
Data delayed at least 15 minutes, as of Nov 22 2024 09:32 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Detection Technology Oyj | -100.00bn | -100.00bn | 203.72m | 464.00 | -- | 2.76 | -- | -- | -- | -- | -- | 5.03 | -- | -- | -- | -- | -- | 9.34 | -- | 11.96 | -- | 47.44 | -- | 8.22 | 3.39 | -- | 0.00 | 53.45 | 5.29 | 2.02 | 7.55 | -18.03 | -14.88 | -9.55 |
| BICO Group AB | 194.42m | -67.91m | 206.41m | 828.00 | -- | 0.8285 | -- | 1.06 | -11.15 | -15.20 | 31.92 | 41.79 | 0.3602 | 2.15 | 4.47 | 2,547,964.00 | -12.62 | -- | -14.44 | -- | 55.70 | -- | -35.03 | -- | 2.23 | -0.5705 | 0.397 | -- | 6.09 | -- | -1,889.33 | -- | -- | -- |
| Onward Medical NV | 0.00 | -35.15m | 207.97m | 99.00 | -- | 7.67 | -- | -- | -1.09 | -1.09 | 0.00 | 0.6079 | 0.00 | -- | -- | 0.00 | -66.40 | -55.70 | -79.20 | -61.60 | -- | -- | -- | -79,513.95 | -- | -- | 0.4855 | -- | -34.62 | -- | -10.40 | -- | 32.59 | -- |
| Medistim ASA | 47.17m | 8.76m | 222.95m | 152.00 | 25.41 | 6.37 | 20.42 | 4.73 | 5.55 | 5.55 | 29.87 | 22.12 | 1.13 | 0.7461 | 7.48 | 3,599,204.00 | 21.05 | 22.93 | 25.53 | 28.52 | 79.12 | 78.25 | 18.58 | 20.64 | 2.75 | -- | 0.0181 | 75.25 | 7.00 | 10.06 | -8.91 | 12.72 | 0.033 | 14.87 |
| Tristel Plc | 50.40m | 7.80m | 252.12m | 213.00 | 32.60 | 6.45 | 22.81 | 5.00 | 0.135 | 0.135 | 0.8714 | 0.6818 | 0.9812 | 1.81 | 5.74 | -- | 15.18 | 9.32 | 17.75 | 10.76 | 80.08 | 80.75 | 15.47 | 11.09 | 3.04 | -- | 0.1532 | 109.35 | 16.45 | 9.89 | 45.46 | 9.99 | 10.13 | 19.53 |
| Nyxoah SA | 5.08m | -52.98m | 271.45m | 147.00 | -- | 2.59 | -- | 53.41 | -1.72 | -1.72 | 0.166 | 3.04 | 0.0366 | 0.5569 | 2.30 | 34,618.53 | -38.20 | -23.73 | -42.88 | -25.98 | 61.75 | 62.42 | -1,042.52 | -1,469.59 | 4.95 | -45.27 | 0.1822 | -- | 40.99 | -- | -38.39 | -- | 100.58 | -- |
| COLTENE Holding AG | 257.11m | 13.29m | 322.98m | 1.19k | 24.35 | 3.00 | 15.62 | 1.26 | 2.06 | 2.06 | 39.89 | 16.73 | 1.27 | 1.38 | 6.06 | 198,668.90 | 6.55 | 10.48 | 11.70 | 18.74 | 64.90 | 62.68 | 5.17 | 7.47 | 0.8619 | 10.18 | 0.3421 | 79.94 | -9.13 | 3.54 | -54.05 | -6.81 | -7.72 | -7.79 |
| Guerbet SA | 826.24m | 32.76m | 332.46m | 2.92k | 10.48 | 0.8533 | 3.72 | 0.4024 | 2.51 | 2.51 | 66.42 | 30.82 | 0.8128 | 0.5493 | 5.56 | 282,958.60 | 3.03 | 1.40 | 4.96 | 1.86 | 78.58 | 76.02 | 3.73 | 1.82 | 1.16 | 3.85 | 0.5073 | 57.82 | 4.30 | -0.0993 | 158.05 | -12.61 | 5.23 | -10.07 |
| Stratec SE | 250.54m | 10.01m | 336.77m | 1.46k | 33.63 | 1.48 | 11.50 | 1.34 | 0.8236 | 0.8236 | 20.61 | 18.74 | 0.5605 | 1.27 | 5.32 | 164,609.70 | 2.24 | 7.07 | 2.85 | 8.20 | 27.04 | 27.32 | 4.00 | 9.70 | 0.9269 | 3.86 | 0.4011 | 40.81 | -4.63 | 6.88 | -55.29 | 3.30 | -2.16 | -7.68 |
| Synektik SA | 143.84m | 19.49m | 343.24m | 164.00 | 17.62 | 7.76 | 15.25 | 2.39 | 9.92 | 9.92 | 73.25 | 22.52 | 1.84 | 26.95 | 6.41 | -- | 24.98 | 15.09 | 39.97 | 23.83 | 26.82 | 24.88 | 13.55 | 11.00 | 1.49 | 45.18 | 0.109 | -- | 39.82 | 35.90 | 61.36 | 56.08 | 50.89 | -- |
| IVF Hartmann Holding AG | 164.62m | 18.99m | 377.27m | 298.00 | 19.86 | 2.48 | 14.96 | 2.29 | 7.35 | 7.35 | 63.72 | 58.84 | 0.8788 | 3.14 | 8.52 | 502,947.40 | 10.14 | 7.29 | 12.06 | 8.90 | 55.21 | 53.29 | 11.54 | 8.30 | 3.95 | -- | 0.0058 | 52.16 | -1.79 | 2.09 | 34.95 | 1.49 | -14.83 | 26.82 |
| medmix AG | 516.49m | -1.94m | 383.85m | 2.70k | -- | 0.7646 | 6.19 | 0.7432 | -0.05 | -0.05 | 11.35 | 11.30 | 0.4778 | 3.40 | 5.58 | 180,474.00 | -0.0996 | 2.06 | -0.1227 | 2.49 | 32.58 | 36.38 | -0.2085 | 4.16 | 1.06 | 2.21 | 0.4361 | 67.70 | 1.99 | 1.40 | -97.41 | -64.36 | 12.01 | -- |
| Ion Beam Applications SA | 465.75m | 7.85m | 399.73m | 1.84k | 49.10 | 4.27 | 20.39 | 0.8582 | 0.2689 | 0.2689 | 15.99 | 3.09 | 0.7721 | 2.15 | 2.70 | 234,517.10 | 1.30 | 1.55 | 6.01 | 4.32 | 34.19 | 35.23 | 1.69 | 2.38 | 0.6372 | 3.77 | 0.3992 | 64.83 | 18.67 | 10.74 | -250.40 | -- | -8.06 | -- |
| CellaVision AB | 63.63m | 12.97m | 441.60m | 228.00 | 34.06 | 6.66 | 26.67 | 6.94 | 6.30 | 6.30 | 30.91 | 32.19 | 0.7849 | 1.91 | 7.26 | 3,233,162.00 | 15.99 | 15.30 | 18.45 | 18.24 | 66.99 | 69.03 | 20.38 | 19.98 | 2.15 | 1,358.86 | 0.044 | 110.18 | 5.94 | 13.17 | 10.12 | 8.00 | 30.45 | 8.45 |
| RaySearch Laboratories AB (publ) | 100.90m | 15.11m | 458.75m | 414.00 | 39.11 | 8.44 | 12.77 | 4.55 | 5.10 | 5.10 | 34.09 | 23.65 | 0.6023 | 5.51 | 3.29 | 3,005,152.00 | 9.02 | 1.29 | 13.69 | 1.88 | 91.06 | 90.57 | 14.97 | 2.55 | 1.27 | 108.61 | 0.3706 | 69.00 | 21.16 | 10.26 | 243.06 | 0.7648 | -1.31 | -- |
| Advanced Medical Solutions Group plc | 157.58m | 13.38m | 535.28m | 1.50k | 40.09 | 1.83 | 19.83 | 3.40 | 0.051 | 0.051 | 0.6011 | 1.12 | 0.3977 | 1.70 | 4.91 | 154,244.70 | 3.38 | 6.54 | 3.64 | 7.06 | 54.45 | 56.75 | 8.49 | 14.82 | 6.80 | -- | 0.2702 | 25.85 | 1.51 | 4.23 | -22.14 | -6.71 | 15.66 | 12.32 |
Data as of Nov 22 2024. Currency figures normalised to Ion Beam Applications SA's reporting currency: Euro EUR
23.67%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Premier Fund Managers Ltd.as of 31 Jul 2024 | 1.91m | 6.32% |
| Belfius Insurance SA NVas of 31 Dec 2023 | 1.19m | 3.93% |
| Van Lanschot Kempen Investment Management NVas of 31 Dec 2023 | 875.39k | 2.89% |
| Paladin Asset Management Investmentaktiengesellschaft TGVas of 31 Dec 2023 | 768.77k | 2.54% |
| BNP Paribas Asset Management Belgium SAas of 30 Aug 2024 | 552.43k | 1.82% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 478.30k | 1.58% |
| Investor Asset Management BVas of 08 Nov 2024 | 441.75k | 1.46% |
| NS Partners Europe SAas of 01 Feb 2024 | 430.66k | 1.42% |
| Econopolis Wealth Management NVas of 30 Jun 2024 | 330.00k | 1.09% |
| Norges Bank Investment Managementas of 13 Feb 2024 | 186.22k | 0.62% |
More ▼
Data from 31 Dec 2023 - 14 Nov 2024Source: FactSet Research Systems Inc.
